

## Profiling tau seeds in aging and across mixed proteinopathies in neurodegenerative diseases



#### Allison Kraus, PhD

Associate Professor, Department of Pathology Associate Director, National Prion Disease Pathology Surveillance Center Case Western Reserve University School of Medicine

## Amyloids

Can assemble into large multimeric deposits (amyloid plaque, NFTs)

Auxiliary associated (co)factors

Can co-occur proximal to other amyloids



### A structural basis for neurodegenerative diseases



 $\alpha$ -Syn

Prion (infectious mammalian)









References: Fitzpatrick et al. 2017; Shi et al 2022; Zhang et al 2020; Schweighhauser et al 2020; Kraus et al. 2021; Hoyt et al. 2022

## The amyloid spectrum in health and disease

Functional amyloids

Transmissible, Pathogenic amyloids

**Prions** 

Innate immune signaling

**Bacterial biofilms** 





Tau filaments of AD



#### Infectious misfolded proteins

Hervas, Si et al., Science 2020

Fitzpatrick, Goedert, Scheres et al., Nature 2017

Kraus, Caughey et al. Mol Cell 2021

## The amyloid spectrum in health and disease



How do co-occurring protein seed pathologies correspond with and/or contribute to neuropathological and clinical outcomes??

### Evaluating seeding activities using real-time quakinginduced conversion (RT-QuIC)



Endpoint dilution analysis to calculate seeding doses

Evaluating 3R/4R, 4R tau and  $\alpha$ -synuclein seeds in the frontal lobe in AD and non-AD cases across different Braak stages

mid frontal lobe



Alzheimer's disease (n=16) Lewy body disease (DLB) (n=13) Lewy body disease (PD) (n=8) Multiple System Atrophy (n=6) Corticobasal degeneration (n=6) Progressive supranuclear palsy (n=6) Controls (Braak 0-II) (n=12)



Braak et al., J Neuropathol Exp Neurol. 2011

David Coughlin, Annie Hiniker, Douglas Galasko Graphics with Biorender.com

## 3R/4R tau seeding activities are prevalent in LBD and other neurodegenerative diseases and correspond with overall Braak stage



Manca, Standke et al., Acta Neuropathologica 2023

3R/4R tau seeding activities correspond with overall AD neuropathologic change



Tau seeds that occur at both early and late stages of accumulation are largely protease resistant and sarkosyl insoluble



#### Manca, Standke et al., Acta Neuropathologica 2023

### The amyloid spectrum in health and disease



## Where do distinct protein seeds (tau, $\alpha$ -syn) and protein seed networks intersect?

### How does this relate to neuropathology and disease?

Features of seeds found at prodromal stages?

Clinical outcome?

# Isoform-selective tau seeding assays to define neuroanatomic distribution of AD versus PSP tau seeds



4 5

-2.5

Coughlin et al., Acta Neuropathol 2022

1.5

RT-QuIC supports highly sensitive and selective detection of co-occurring  $\alpha$ -synuclein and tau seeds & strains in the brain



## Tau and $\alpha$ -synuclein seeding activities precede overt neuropathology, and prevalently co-occur across neurodegenerative diseases



### Tau: A structural basis for disease



# Understanding heterogeneity in core-sharing tauopathies: PART and AD





# Brain region specific 3R/4R tau seeding activities differentiate ADNC and PART







### Tau seeding activity correlates with global and region-specific cognition and longitudinal decline



Browne, Smirnov, et al., Under review

# Biochemically distinct cortical tau species differentiate ADNC and PART



a µg SI Material per mg Brain Tissue



### Distinct midfrontal tau PTMs mark highestseeding ADNC cases





#### Browne, Smirnov, et al., Under review



Biorender.com

## The amyloid spectrum in health and disease

- 3R/4R tau seeds occur broadly across neurodegenerative diseases, including in LBD
- Prevalent protein seed co-occurrence (3R/4R, 4R tau and  $\alpha$ -synuclein) is observed in both primary synucleinopathy and tau-based diseases
- α-synuclein and tau seeding activities are observed at 100% prevalence in Lewy body disease cases examined, and differ from the prevalence of seed co-occurrence and levels thereof in ADNC, PART or 4R tauopathies
- Tau PTMs and seeding activities differ between PART and ADNC; evidence that the biochemical complexity of seeding proteoforms differs in distinct clinicopathologically relevant microenvironments

Implications for mechanisms of disease, biomarker development?

### Acknowledgements

We thank the families and donors who have made this research possible.

### Collaborators:

CWRU **Brian Appleby** Mark Cohen Xiongwei Zhu Andrew Pieper Kunpeng Li Sudha Chakrapani

CCF

Jim Leverenz Lynn Bekris & colleagues with the CADRC UH Steve Gunzler Linda Cummings Kenneth Rodriguez

Dartmouth Surachai Supattapone

Yale Kurt Zilm Marcus Tuttle USC Annie Hiniker

UCSD David Coughlin **Douglas Galasko** Yongya Kim **Donald Pizzo** 

Harvard, Brigham Denis Smirnov

RML, NIAID, NIH Christina Orru Andrew Hughson **Byron Caughey** Forrest Hoyt Cindi Schwartz Bryan Hansen **Dave Dorward** Efrosini Artikis Brent Race Austin Athman

UF





Browne



Colin Shin



Zamore





Caitlin Swanberg MS

Iris Peng

Lab alumni:

Mikayla Huntley Olivia Thomas, MPH





Matteo Antonio Cornacchia MS

Brian Kona

Standke

Adi

Ashley Chow Chapanova

Layla Seaton

### With support from: **James and Pearl Zeller Fund**



Cleveland **Alzheimer's Disease Research Center** 

**CASE WESTERN RESERVE UNIVERSITY** 

**The Britton Fund** 



CREUTZFELDT-JAKOB DISEASE FOUNDATION, INC. Supporting Families Affected by Prion Disease

### **Dementia with Lewy Bodies Consortium**

THE MICHAEL J. FOX FOUNDATION

alzheimer's **N** association<sup>°</sup>







National Institutes of Health

(R01NS118760, R01AG067607)



